Jump to content


A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome

Jeffrey Roberts

Recommended Posts

Jeffrey Roberts


To evaluate the safety and tolerability, treatment effect on abdominal pain, and dose response of MD-7246 administered orally to patients with diarrhea-predominant irritable bowel syndrome (IBS-D).

Study Start Date: May 1, 2019

Ages Eligible for Study:    18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:    All
Inclusion Criteria:
  • Patient meets the Rome IV criteria for diagnosis of IBS-D
  • Patient maintains a minimum level of compliance with daily diary

Exclusion Criteria:

  • Patient has clinically significant findings on a physical examination and/or clinical laboratory tests
  • Patient has symptoms of or been diagnosed with a medical condition that may contribute to abdominal pain
  • Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease or condition that can affect GI motility
  • Patient has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments


Boston Clinical Trials Inc

Boston, Massachusetts, United States, 02131 

Study Coordinator    617-477-4868


Additional locations are listed at ClinicalTrials.gov (Identifier): NCT03931785

Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.


  • Create New...